Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Because _bbb_, one of the assistant-moderators, can't post anymore until June 13th and LongVestor is still on a business trip, it is all up to you Bigplay777 to keep things going around here.
Luckily we will all be in a good mood soon. Today or tomorrow we can expect the Q3 results. And monday after the China Rising meeting we can expect a lot of new investors (I hope). It was nice that today we were at $8 dollar again, that has been a few months ago.
I am looking forward to reading the outlook that we'll get in the next PR, also it would be nice to see some things clarified that we had on our list with questions. We'll know more next week I guess, after the conference call. Is anyone here going to participate?
Just read your post over there, thanks for mentioning JGBO. Who knows if it will help, we'll see!
The first answer to one of our questions:
1. What are the requirements for uplisting: 4 or 5 dollar, is that bid or closing price for 30/60/90 days?
"Hello 996,
Here is the answer to your first question by Nasdaq officials.
The price requirement is still $4. Good news is that $4 can qualify for Global Market now.
As for days, so long as the company is not qualifying under standard 2 of the capital market or standard 3 of global market, then they would require to have a 90 consecutive trading days prior to applying for listing. Otherwise, there is no trading day requirement. However, Nasdaq generally likes to see them trading above 4 dollar for 5 days prior to approval.
And the whole reviewing and approval process normally takes about one month.
Thanks.
Karen Wang
Sr. Account Executive
CCG Investor Relations - Strategic Communications"
That's why I've mailed the earlier posted questions to Ms. Sung and Mr. Coulson, hopefully they will give clarity in these matters in the next CC.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37683819
Jiangbo
JGBO former GNPH is a GOOD buy in my opinion. Will uplist within 6-12 months. This fiscal year (ending june 30th) will give approx 111-116 million dollar revenue and 40-43 million dollar in operating income.
Last year that was 120 million vs. 32 million. In that fiscal year net income was 22.5 million dollar.
There are about 10.5 million shares outstanding.
There are four major new drugs in the pipeline. To be released within 1 year (?).
http://www.genesispharmaceuticals.com/product2.php?fir_lineid=80
Recently the company acquired Hongrui, a producer of 22 traditional chinese medicines. This will add extra revenues.
Using those numbers for starters I guesstimate the following scenarios:
Long-Vestor, you are right in your statement that these assets would also be used to pay for legal costs etc.
But once these shares where worth more than 6 million dollar. No way the legal costs where more than that amount. Jiangbo hasn't sold the assets yet, so chances are that the selling of these assets (in the future) will more than suffice for the legal costs that where made.
We won't know for sure untill Jiangbo opens up about it.
JMHO
If all goes well they have their Q3 results out by then, so there should be a lot of fun stuff to talk about.
Seems reasonable. But look how nice it could be if we reach a nice PE ratio.
First table uses a PE of 5~10 (after uplisting)
The second table uses a PE of 5~15 (after uplisting)
But none of this will ever happen if we don't uplist. So let's go Jiangbo !
check again
I have an answer from Crocker Coulson: he says they will be adressing these questions the best they can in the next conference call.
I've sent her e-mails before and never got an answer. I thought maybe they aren't allowed to answer such questions without making them public to everyone else. Trading with insider knowledge or something like that ?!?! And that therefor they only answer such questions in a press conference or conference call.
But anyway, I can always try so I will e-mail her today. I'll keep you guys posted!
It's nice to start trading under a new symbol. Just like we can start all fresh...
Go go go JGBO !
PS Mail has been sent...
5
Is this the silence before the storm ?
6
Doesn't anyone have any questions to add to our list?
Wouldn't it be wise to make a sticky out of the post with the questionlist? Else it might drop down too far, and no-one will notice. I think the questions are worth being answered by the company itself!
I don't know, haven't got a crystal ball either. But I do know we won't see $20-30 if we don't uplist and get those three drugs and LFAA out on the market. As always, time wil tell...
I personally don't exepect to see 50-60 within the next 2-3 years...but who knows!
What would be a reasonable shareprice in the short term (< 6 months) and in the long run (after uplisting, so approx. 1 year from now) ?
I haven't made money yet, so can't afford the lekkerbekjes. you know my goal: pre-reverse split $1
Everyone can ad questions to this list, just copy/paste and ad your own questions. Then the people who call in can use the list... I'll start out with the questions BigGreen101 has asked and I'll ad some of my own.
1. What are the requirements for uplisting: 4 or 5 dollar, is that bid or closing price for 30/60/90 days?
2. Why does uplisting have to take yet another 6-12 months?
3. What is the status of the drugs mentioned in last summers 10Q? 2Q 2009 is done and those drugs have not been SFDA approved.
4. What is happening with LFAA drug? Is it through Phase III clinical trials? Has GNPH negotiated a final purchase price?
5. What is the normal time frame to have a drug reviewed by SFDA? For the FDA in the USA, a review of a new drug application takes roughly 18 months.
6. How many shares have already been bought back as announced in the 2 million dollar share-buyback program?
7. Can you give an actual number on shares that are held by insiders, Pope, Ardsley?
8. How many shares of GHII and LTUS does GNPH still own? Are there plans on sellig these?
9. What has happened to the once promised dividend for the pre-merger US shareholders? Can this be cancelled without any consequences?
10. Are there any new drugs in development besides the three in the pipeline and the LFAA? Or is GNPH first going to concentrate on those total four and the drugs acquired with the acquisition of Hongrui?
11. Can we expect more acquisitions or a merger within a year from now?
12. Is transfering money out of the PRC to the US still an issue?
13. Are you considering paying a dividend to all shareholders ?(not as in question 9).
On May 18th the China Rising conference will be held. That day all 30 attending companies will give a presentation. GNPH is scheduled as one of the first. All those new, whealthy investors will be fresh for the start of the day and listening carefully, would be nice to see a lot of new investors buying in that day... Take us to the next level!
http://www.meetmax.com/sched/ccgir/~public/conference_presentations.html?event_id=3910
http://www.meetmax.com/sched/ccgir/~public/conference_activities.html?event_id=3910
I see there is a Nasdaq closing bell meeting scheduled also. Nice occasion for GNPH to announce their (unexpected) short term uplisting...(I know, wishfull thinking)
7
And still consolidating on the current level...nice but should be better: $10 anyone?
8
Furthermore nothing new to report, sorry.
Except we'll all have to be patient.
Float get's less every day, one day that will cause a fast sprint to much higher levels...
At least the assets in the stockportfolio of GNPH are doing well:
Lotus and Gold Horse are generating a lot of value today. So the intrinsic value of GNPH is rising as well. I am not sure how many shares of these companies GNPH still owns. I know that in 2008 at some time it where 2.5 million shares of LTUS and 8 million shares of GHII
http://finance.yahoo.com/q?s=ghii.ob
http://finance.yahoo.com/q?s=LTUS.OB
If uplisting is 6-12 months away, why should GNPH be buying their own shares right now? ($2 million share buyback).
It can't be because they want to keep the pps > $4. Because 2 million dollar won't last 6-12 months.
The only reason I can think of: because the shareprice is extremely low!
My bet is all posters here own more than 100 shares Why else would we be posting...
If you're no. 1 that makes me no. 2
One of the uplisting requirements seems to be that GNPH has to have at least 400 round lot shareholders. That means 400 shareholders with at least 100 shares each.
Check this page http://www.pinksheets.com/pink/quote/quote.jsp?symbol=gnph under the tab "Company Info", it states "Number of Share Holders of Record
955 as of Sep 29, 2008"
Of course the number will have changed since Sept. 2008 but my guesstimate is we still have at least 400 shareholders with more than 100 shares each.
Wow, that is a nice skyline!
I must admit I am not 100% sure so I understand your doubts. As always: time will tell.
How are you doing in the land of the rising sun ?
Long, you ask a question: do we have at least three registered and active Market Makers?
Isn't this the answer:
When you look at the level II of GNPH I always see more than three marketmakers at the bid and ask, isn't that what they mean by this rule?
Furthermore I think whe have a lot more than 400 round lot holders, I believe I have seen a site where it stated how many shareholders we had, can't find the link... I'll be searching.
Your question: "Where is the LFAA medicine? I thought that was going to be a cash cow. It seems that everything is taking it dandy time with GNPH."
Is a legit question, but they are working on it so it seems. It has not completely disappeared, the other three drugs are pending and that specific medicine (LFAA) hasn't reached the final stage yet?
http://www.jiangbopharma.com/product2.php?fir_lineid=80
The lack of new messages here means everybody is a little bit disappointed by the timeschedule for uplisting?
I guess I am, 6-12 months is a LONG wait...
Jiangbo Pharma aims high as health care reform rolls out - CFO
Shanghai April 24
By Karl Zhong, Interfax
Jiangbo Pharmaceuticals Inc., a U.S.-incorporated pharmaceutical company that operates primarily in China and was formerly known as Genesis Pharmaceuticals Enterprises Inc.,is well positioned to benefit from the health care reform given its sound pharmaceutical marketing network and expanded product portfolio, according to Elsa Sung, the company's chief financial officer.
In January this year, the company's wholly-owned subsidiary Laiyang Jiangbo Pharmaceutical Co. Ltd. entered into an asset transfer agreement with Hongrui Pharmaceuticals Co. Ltd. for the purchase of most of Hongrui Pharma's assets, including the production rights to 22 types of traditional Chinese medicines (TCM), at a deal price of RMB 110 million ($16.11 million).
“The acquisition has expanded our product portfolio. Two of the TCM medicines in particular, a drug to treat bone marrow inflammation and a cough suppressant, have great market potential,” Sung said.
According to Sung, the Chinese government's expansion of the new rural cooperative medical insurance program as part of the health care reform will help to promote the company's TCM sales.
Jiangbo Pharma expects to generate fast growth sales for the TCM products by leveraging on its sound marketing network, which consists of 470 full-time sales representatives and 620 part-time representatives in 30 provinces, cities and regions across China.
“Regional distributors are more familiar with the situation in their local markets. Jiangbo Pharma will benefit by working closely with these distributors, especially in the future when essential drugs [which are commonly purchased generic drugs that patients receive reimbursements for under their medical insurance] are distributed on a regional basis,” Sung said. The company recently lowered its wholesale prices in a bid to motivate regional distributors to improve sales.
While maintaining sales of its existing products and growing the market shares of new products form Jiangbo Pharma's short-term strategy, Sung said the company is looking towards merger and acquisition (M & A) deals and strengthening its research and development (R & D) efforts in the long run.
More M & A opportunities have opened up as a result of the economic downturn and the company is eyeing drug developers that hold the rights to national class one or two new drugs, the highest levels of innovation in China, according to Sung.
With regards to R & D efforts, Jiangbo Pharma put about 3.34 percent of its sales revenue towards R & D in the second half of last year, considerably higher than what many other generic drug manufacturers in China allocated to R & D. “We have been working with Shandong University and the Chinese Academy of Sciences (CAS) on new drug development, which gives us priority in commercializing the products they develop,” Sung said.
At the moment, the company has three drugs that are awaiting final approval from the State Food and Drug Administration (SFDA), including Bezoar Yijin tablets to treat inflammation, felodipine sustained-release tablets for hypertension, and Yuandu Hanbi capsules to relieve arthritis pain.
OTCBB-listed Jiangbo Pharma is also currently preparing to list on the Nasdaq within the next six to 12 months, Sung said.
Jiangbo Pharma is located in an economic development zone in Shandong Province's Laiyang City and produces both western and TCM drugs. Its sales revenue amounted to $60.5 million in the second half of last year, up 40.2 percent from the same period of the previous year.
Links:
http://www.interfax.cn/news/9277/
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_G/threadview?m=te&bn=31759&tid=5910&mid=5910&tof=1&frt=2#5910
Haven't found any mention of GNPH in the video or am I missing something ?!?!?!
Hmmm, short interest went up +400% to approx. 27,000 shares in April, will that mean marketmakers will be manipulating the shareprice to buyback lower?
Or will it cause a short-squeeze and thus a higher shareprice? One thing for sure: we can expect some movement in the next couple of days/weeks.
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=gnph
http://www.otcbb.com/asp/OTCE_Short_Interest.asp
More investor awareness:
http://www.thestreet.com/_yahoo/video/10491827/china-watch-chinamerica-holdings.html?cm_ven=YAHOOV&cm_cat=FREE&cm_ite=NA&s=1#21112476001
GNPH is mentioned (haven't checked it out myself yet).
Is Chinamerica a well known /important fund?
http://www.chinamericafund.com/default.aspx
Nice work Long, but hey your the man of the charts... The question is not wether we reach $13.50, neither is the question when, cause I know those answers already. Yes we're gonna reach $13.50 and my guess is it will be within a few months. The big question is: are you gonna take profits at that level. I for sure won't
Maye at 31.50 or 35.10 or 51.30 or 53.10 but definitley not at 13.50
Is business going well in Japan?
Thanks _bbb_. Then I hope they'll let us know through a PR if they bought some. Would be a sign of strength, shouldn't go unnoticed I would think...
This was the 35th tradingday (48th calendar day) we've closed above $4. We're on our way to uplist...
By the way approx. 180,000 shares were trades in those 35 days.
Do share buybacks have to be reported as an Insider Trade (From 4) or how does this work? Within how much time such a report has to be filed?
The 3 TCM's add about 7.3 million in 2010 to the revenues> Hongrui had 22 medicines in total, so the total of 22 TCM's will add approx. 7 x 7.3 = $ 50 million in 2010 ~ 2011? Or am I over-enthusiastic here?
Genesis Pharmaceuticals today announced that it began marketing and selling three Traditional Chinese Medicines ("TCMs").
Sales of these three products are expected to be $1.5 million in the Company's fiscal year 2009, which ends on June 30, 2009, and an estimated $7.3 million in fiscal year 2010.
The Company recently purchased 22 TCMs with SFDA drug regulatory agency approvals for manufacturing and distribution from Hongrui Pharmaceuticals. The three TCMs which Genesis is now beginning to market and distribute are the first three products Genesis acquired from Hongrui to be relabeled and sold under Genesis' brand name "Jiangbo." All three Hongrui products are being sold through the 28 independent distributors used by Genesis.
"We are pleased to launch these three products so quickly after taking control over Hongrui," said Mr. Wubo Cao, Chief Executive Officer of Genesis. "Generally speaking, TCMs are popular in rural China because they are less expensive than western medicines. We plan to increase our marketing and sales efforts for all of our TCM products in rural areas in conjunction with government plans to expand healthcare services there."
Full PR can be read here:
http://finance.yahoo.com/news/Genesis-Pharmaceuticals-prnews-14995202.html?.v=4
Only good things happening now, that's nice for once! Let's not forget things will get even better when we see the positive effects of the recent acquisition of Hongrui and it's 22 medicines on the numbers! They must contribute something positive to revenues and profits.